ClinicalTrials.gg
RecruitingNCT07228793RUS_EYSUpdated Nov 16, 2026

Natural History Study of Patients With EYS-Associated RP

An observational study in Retinitis Pigmentosa and Eye Diseases, sponsored by Sensor Technology for Deafblind. Recruiting at 1 site in Russia. Open to participants aged 14 Years to 100 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by Sensor Technology for Deafblind · Observational

How we know

From the registry’s dates

  • Started Nov 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
45
Ages
14 Years to 100 Years
Sex
All
01

Study summary

This natural history study of patients with EYS mutations from Russia and former CIS (Commonwealth of Independent States) territories will accelerate the development of outcome measures for clinical trials. Sensitive, reliable outcome measures of retinal degeneration will greatly facilitate development of treatments for retinitis pigmentosa due to EYS mutations. This approach helps to develop experimental treatment protocol, and assessing its effectiveness.

The goals and expected impact of this natural history study are to:

  1. Describe the natural history of retinal degeneration in patients with biallelic mutations in EYS gene in Russia and former CIS territories.
  2. Identify sensitive structural and functional outcome measures to use for future multicenter clinical trials in EYS-related retinal degeneration in Russia and former CIS territories.
  3. Identify well-defined subpopulations for future clinical trials of investigative treatments for EYS-related retinal degeneration in Russia and former CIS territories.
Read the detailed description
  1. Characterize the natural history of retinal degeneration associated with biallelic pathogenic mutations in the EYS gene over 4 years, as measured using functional, structural, and patient-reported outcome measures
  2. Investigate whether structural outcome measures can be validated as surrogates for functional outcomes in individuals with biallelic pathogenic mutations in the EYS gene
  3. Evaluate risk factors (genotype, phenotype, environmental, and comorbidities) for progression of the outcome measures at 4 years in individuals with biallelic pathogenic mutations in the EYS gene
  4. Evaluate variability and symmetry of left and right eye outcomes over 4 years in individuals with biallelic pathogenic mutations in the EYS gene
02

Conditions studied

  • Retinitis Pigmentosa
  • Eye Diseases

Keywords

  • EYS mutation
  • RP
  • Retinitis pigmentosa
03

In context

Retinitis Pigmentosa

281 studies on the registry are indexed under Retinitis Pigmentosa; 74 are open to participants now.

This study's planned enrollment of 45 is below the median of 52 across 89 observational studies indexed under Retinitis Pigmentosa.

Browse Retinitis Pigmentosa studies →

Lead sponsor

Sensor Technology for Deafblind is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years to 100 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Potential eligibility may be assessed as part of a routine care examination by an investigator prior to obtaining informed consent, as part of usual care, by referral from another physician, or self-referral.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to participate in the study and able to communicate consent during the consent process
  2. Ability to return for all study visits over 48 months
  3. Age ≥ 18 years
  4. Must meet one of the Genetic Screening Criteria, defined below:

Screening Group A: At least 2 disease-causing variants in the EYS gene which are homozygous or heterozygous in trans, based on a report from a clinically-certified lab (or a report from a research lab that has been pre-approved by the Study Committee) Screening Group B: Only 1 disease-causing variant in the EYS gene, based on a report from a clinically-certified lab (or a report from a research lab which has been pre-approved by the Study Committee) Screening Group C: At least 2 disease-causing variants in the EYS gene which are unknown phase, based on a report from a clinically-certified lab (or a report from a research lab which has been pre-approved by the Study Committee) Note pertaining to all Screening Groups: if a participant has a variant(s) of unknown significance, he/she would still qualify as long as there is at least 1 disease-causing variant(s) on the EYS gene.

Ocular Inclusion Criteria:

Both eyes must meet all of the following:

  1. Clinical diagnosis of retinal dystrophy
  2. Clear ocular media and adequate pupil dilation to permit good quality photographic imaging

Exclusion criteria

Exclusion Criteria:

  1. Mutations in genes that cause autosomal dominant retinitis pigmentosa (ADRP), X-linked retinitis pigmentosa (RP), or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than EYS.
  2. Expected to enter experimental treatment trial at any time during this study
  3. History of more than 1 year of cumulative treatment, at any time, with an agent associated with pigmentary retinopathy (including hydroxychloroquine, chloroquine, thioridazine, and deferoxamine)

Ocular exclusion Criteria:

If either eye has any of the following, the participant is not eligible:

  • Current vitreous hemorrhage
  • Current or any history of rhegmatogenous retinal detachment
  • Current or any history of (e.g., prior to cataract or refractive surgery) spherical equivalent of the refractive error worse than -8 Diopters of myopia
  • History of intraocular surgery (e.g., cataract surgery, vitrectomy, penetrating keratoplasty, or LASIK) within the last 3 months
  • Current or any history of confirmed diagnosis of glaucoma (e.g., based on glaucomatous visual functions changes or nerve changes, or history of glaucoma filtering surgery)
  • Current or any history of retinal vascular occlusion or proliferative diabetic retinopathy
  • History or current evidence of ocular disease that, in the opinion of the investigator, may confound assessment of visual function
  • History or evidence of active treatment for retinitis pigmentosa that could affect the progression of retinal degeneration, including:
  • Any use of ocular stem cell or gene therapy
  • Treatment with an ophthalmic oligonucleotide within the last 9 months (last treatment date is less than 9 months prior to Screening Visit date)
  • Treatment with any other product within five times the expected half-life of the product (time from last treatment date to Screening Visit date is at least 5 times the half-life of the given product)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
45 participants (estimated)
Target follow-up
5 Years
Patient registry
Yes
Biospecimen retention
Samples with dna

Groups and cohorts

  • Vision Cohort 1

    Participants with the better eye Screening Visit decimal visual acuity of 0.4 or more and visual field diameter 10 degrees or more in every meridian of the central field.

    Diagnostic Test: Whole exome/genome sequencing

  • Vision Cohort 2

    Participants with the better eye Screening Visit decimal visual acuity 0.15 - 0.35 and visual field diameter less than 10 degrees in any meridian of the central field)

    Diagnostic Test: Whole exome/genome sequencing

  • Vision Cohort 3

    Participants with the better eye Screening Visit decimal visual acuity 0.14 or less.

    Diagnostic Test: Whole exome/genome sequencing

Interventions

  • Diagnostic testWhole exome/genome sequencing

    Next generation sequencing and segregation analysis or long read sequencing for confirmation of biallelic mutations (in trans-position)

06

What researchers measure

Primary outcomes

  1. Change in Visual Field Sensitivity

    Measured by static perimetry with topographic analysis and assessed by a certified reading center for cohorts 1 and 2.

    Time frame: Baseline and every year until study completion (4 years)

  2. Change in Retinal Function

    Measured by full-field electroretinogram (ERG) amplitudes and timing in response to rod- and cone-specific stimuli for cohorts 1 and 2.

    Time frame: Baseline and 4 year follow-up visit.

Secondary outcomes

  1. Change in Best Corrected Visual Acuity

    Measured on Golovina-Sivtsev charts

    Time frame: Screening visit and every year until study completion (4 years) for cohort 1&2. Screening visit and 48 month follow-up for cohort 3.

  2. Change in Mean Retinal Sensitivity

    Measured by fundus-guided microperimetry (MP) and assessed by a certified reading center for cohorts 1 and 2.

    Time frame: Baseline and every year until study completion (4 years)

  3. Change in Best Corrected Low Luminance visual acuity

    Measured by letter score

    Time frame: Screening visit and every year until study completion (4 years) for cohort 1&2. Screening visit and 48 month follow-up for cohort 3.

  4. Change in Contrast Sensitivity Function

    Measured by Zebra software for cohorts 1 and 2.

    Time frame: Baseline and every year until study completion (4 years).

  5. Change in Ellipsoid zone (EZ) area

    Measured by spectral domain optical coherence tomography (SD-OCT) and assessed by a certified expert

    Time frame: Baseline and every year until study completion (4 years) for cohorts 1 and 2. Baseline and 4 year follow-up for cohort 3.

  6. Explore qualitative and quantitative categorization of Fundus Autofluorescence (FAF) pattern

    Assessed by a certified expert

    Time frame: Baseline and every year until study completion (4 years) for cohorts 1 and 2. Baseline and 4 year follow-up for cohort 3.

Other outcomes

  1. Patient Reported Outcomes for Vision Cohorts 1, 2 and 3

    Measured by modified MRDQ (Michigan Retinal Degeneration Questionnaire)

    Time frame: Baseline and 4 year follow-up visit

07

Study locations

1 of 1 sites recruiting
  • Oftalmic Clinical Research Center
    Moscow, 125167, Russia
    Recruiting
    • Marianna E Weener, MD, PhD · Contactinfo@oftalmic.com · +7 903 758 66 19
    • Natella V Chincharauli, MD, PhD · Principal investigator
    • Maria A Shilova, MD · Sub investigator
08

References and documents

Individual participant data

Plan to share: Yes — A de-identified database will be placed in the public domain on the Oftalmic public website after the completion of each protocol and publication of the manuscript.

Supporting information: Clinical study report

Time frame: After manuscript is published

Access criteria: Users accessing data must enter an email address

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Dec 2029, 49 months after the start.

Of 49 observational studies under Retinitis Pigmentosa, half reached primary completion within 71 months of starting (the median), counting those still running; a quarter within 23. This study's planned 49 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 14, 2025
StartActual
Nov 7, 2025
Primary completionEst.
Dec 15, 2029
CompletionEst.
Mar 30, 2030
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Site contacts
Changed at 1 site. See the sites
Show the site
  • Oftalmic Clinical Research Center · Moscow, RussiaContact added (no phone or email listed)Contact added (no phone or email listed)
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Oftalmic Clinical Research Center · Moscow, RussiaContact added (no phone or email listed)Contact added (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07228793
Lead sponsor
Sensor Technology for Deafblind
Collaborators
Russian RetinaFond
Responsible party
Marianna E. Weener (MD, PhD, Medical Center Oftalmika) — Principal investigator
First posted
Nov 14, 2025
Start date
Nov 7, 2025
Primary completion
Dec 15, 2029 (estimated)
Completion
Mar 30, 2030 (estimated)
Last update
Nov 16, 2026

Study contacts

Olga Luneva
Contact
info@oftalmic.com
+7 9629412912
Marianna Weener, MD, PhD
principal investigator · Oftalmic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion